QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
NYSE:BMY

Bristol-Myers Squibb Stock Competitors

$76.91
+1.11 (+1.46%)
(As of 05/16/2022 04:00 PM ET)
Add
Compare
Today's Range
$76.08
$77.25
50-Day Range
$68.13
$77.77
52-Week Range
$53.22
$78.17
Volume
13.44 million shs
Average Volume
15.03 million shs
Market Capitalization
$163.75 billion
P/E Ratio
27.27
Dividend Yield
2.85%
Beta
0.49

Bristol-Myers Squibb (NYSE:BMY) Vs. JNJ, PFE, LLY, ABBV, MRK, ZTS, RPRX, HZNP, JAZZ, and PRGO

Should you be buying Bristol-Myers Squibb stock or one of its competitors? The main competitors of Bristol-Myers Squibb include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), and Perrigo (PRGO). These companies are all part of the "pharmaceuticals" industry.

Bristol-Myers Squibb vs.

Johnson & Johnson (NYSE:JNJ) and Bristol-Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Johnson & Johnson has higher revenue and earnings than Bristol-Myers Squibb. Johnson & Johnson is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$93.78 billion5.00$20.88 billion$7.4224.00
Bristol-Myers Squibb$46.39 billion3.53$6.99 billion$2.8227.27

Johnson & Johnson presently has a consensus target price of $191.33, suggesting a potential upside of 7.44%. Bristol-Myers Squibb has a consensus target price of $71.33, suggesting a potential downside of 7.25%. Given Johnson & Johnson's stronger consensus rating and higher probable upside, equities research analysts plainly believe Johnson & Johnson is more favorable than Bristol-Myers Squibb.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Johnson & Johnson
0 Sell rating(s)
4 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.56
Bristol-Myers Squibb
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.44

Johnson & Johnson has a net margin of 20.90% compared to Bristol-Myers Squibb's net margin of 13.31%. Bristol-Myers Squibb's return on equity of 48.37% beat Johnson & Johnson's return on equity.

Company Net Margins Return on Equity Return on Assets
Johnson & Johnson 20.90% 36.59% 14.75%
Bristol-Myers Squibb 13.31% 48.37% 15.80%

68.8% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 73.1% of Bristol-Myers Squibb shares are owned by institutional investors. 0.4% of Johnson & Johnson shares are owned by company insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Bristol-Myers Squibb had 12 more articles in the media than Johnson & Johnson. MarketBeat recorded 25 mentions for Bristol-Myers Squibb and 13 mentions for Johnson & Johnson. Johnson & Johnson's average media sentiment score of 0.33 beat Bristol-Myers Squibb's score of 0.05 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Johnson & Johnson
2 Very Positive mention(s)
1 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Bristol-Myers Squibb
1 Very Positive mention(s)
4 Positive mention(s)
13 Neutral mention(s)
3 Negative mention(s)
3 Very Negative mention(s)
Neutral

Bristol-Myers Squibb received 11 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 68.55% of users gave Bristol-Myers Squibb an outperform vote while only 65.88% of users gave Johnson & Johnson an outperform vote.

CompanyUnderperformOutperform
Johnson & JohnsonOutperform Votes
1035
65.88%
Underperform Votes
536
34.12%
Bristol-Myers SquibbOutperform Votes
1046
68.55%
Underperform Votes
480
31.45%

Johnson & Johnson has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500.

Johnson & Johnson pays an annual dividend of $4.24 per share and has a dividend yield of 2.4%. Bristol-Myers Squibb pays an annual dividend of $2.16 per share and has a dividend yield of 2.8%. Johnson & Johnson pays out 57.1% of its earnings in the form of a dividend. Bristol-Myers Squibb pays out 76.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson has increased its dividend for 61 consecutive years and Bristol-Myers Squibb has increased its dividend for 16 consecutive years.

Summary

Johnson & Johnson beats Bristol-Myers Squibb on 12 of the 20 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Bristol-Myers Squibb (NYSE:BMY) vs. Its Competitors

MetricBristol-Myers SquibbPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$163.75B$5.60B$4.25B$13.51B
Dividend Yield2.85%2.53%2.17%3.45%
P/E Ratio27.2712.2214.0817.77
Price / Sales3.53330.232,288.6727.66
Price / Cash6.1120.2522.5636.09
Price / Book5.183.874.039.18
Net Income$6.99B$191.89M$164.30M$882.66M
7 Day Performance0.84%1.47%0.82%0.90%
1 Month Performance-0.77%-20.73%-17.83%-9.05%
1 Year Performance18.54%-43.50%-28.39%-10.11%

Bristol-Myers Squibb Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JNJ
Johnson & Johnson
2.7937 of 5 stars
$178.08
+0.7%
$191.33
+7.4%
+3.9%$468.60B$93.78B24.00141,700
PFE
Pfizer
3.1155 of 5 stars
$50.67
+1.5%
$57.32
+13.1%
+24.7%$286.17B$81.29B11.6279,000Insider Selling
LLY
Eli Lilly and
2.9504 of 5 stars
$299.38
+2.7%
$306.00
+2.2%
+48.6%$284.46B$28.32B44.3535,000Ex-Dividend
Short Interest ↓
ABBV
AbbVie
2.7885 of 5 stars
$155.47
+1.3%
$159.44
+2.6%
+31.8%$274.73B$56.20B22.3150,000
MRK
Merck & Co., Inc.
2.3331 of 5 stars
$92.32
+2.1%
$91.27
-1.1%
+15.5%$233.46B$48.70B16.5268,000
ZTS
Zoetis
2.7548 of 5 stars
$165.50
+0.1%
$234.17
+41.5%
-4.0%$77.89B$7.78B37.9612,100Short Interest ↑
RPRX
Royalty Pharma
3.0231 of 5 stars
$40.26
+0.8%
$51.17
+27.1%
-1.9%$24.44B$2.29B40.2651Analyst Report
Insider Selling
HZNP
Horizon Therapeutics Public
2.55 of 5 stars
$90.82
+0.4%
$137.38
+51.3%
-1.9%$20.88B$3.23B24.881,890Insider Selling
JAZZ
Jazz Pharmaceuticals
2.6333 of 5 stars
$147.15
+0.5%
$208.14
+41.4%
-18.2%$9.17B$3.09B-19.593,200
PRGO
Perrigo
3.2398 of 5 stars
$37.35
+1.6%
$55.33
+48.1%
-19.8%$5.03B$4.14B-57.469,900Earnings Report
Analyst Revision
PCRX
Pacira BioSciences
2.1729 of 5 stars
$63.54
+3.2%
$82.00
+29.1%
-1.1%$2.89B$541.53M75.64697
CORT
Corcept Therapeutics
2.5498 of 5 stars
$19.04
+0.5%
$29.67
+55.8%
-10.8%$2.02B$365.98M20.92238
SUPN
Supernus Pharmaceuticals
1.6864 of 5 stars
$27.44
+2.4%
$44.00
+60.3%
-12.3%$1.47B$579.78M21.11575Earnings Report
NKTR
Nektar Therapeutics
2.4198 of 5 stars
$3.88
-2.8%
$13.17
+239.3%
-79.0%$722.74M$101.91M-1.45740
ENDP
Endo International
1.8148 of 5 stars
$1.15
-4.2%
$3.00
+160.9%
-78.6%$270.38M$2.99B-0.373,103Gap Up
OMER
Omeros
2.1481 of 5 stars
$3.10
-3.1%
$30.40
+880.6%
-82.4%$194.46M$73.81M0.99213Earnings Report
Analyst Revision
PRTK
Paratek Pharmaceuticals
1.9481 of 5 stars
$1.97
-2.5%
$15.50
+686.8%
-73.4%$107.32M$130.16M-1.70207
ASMB
Assembly Biosciences
2.0598 of 5 stars
$1.61
+4.5%
$8.15
+406.2%
-61.1%$77.47M$6.25M-0.57102Earnings Report
Gap Down
CPIX
Cumberland Pharmaceuticals
1.5648 of 5 stars
$2.25
+0.9%
N/A-19.5%$33.39M$35.99M-6.6283Earnings Report
Analyst Report
Gap Up
LCI
Lannett
2.4648 of 5 stars
$0.54
flat
$6.00
+1,015.4%
-88.2%$23.10M$478.78M-0.07810Analyst Report
Short Interest ↓
This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.